News

STA®-Rivaroxaban Calibrator & STA®-Rivaroxaban Control

Rivaroxaban is an oral anticoagulant, direct factor Xa inhibitor, developed by Bayer HealthCare and sold under the trade name Xarelto®. It is approved in three indications in Europe: prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors, treatment of deep vein thrombosis (DVT) and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT in adults and prevention of VTE in adult patients undergoing elective hip or knee replacement surgery.

STic Expert® HIT

For every Heparin Induced Thrombocytopenia (HIT) suspicion. A rapid and specific exclusion of Heparin Induced Thrombocytopenia in 10 minutes. Diagnosing and treating Heparin Induced Thrombocytopenia (HIT) represent a challenge for many clinicians. STic Expert® HIT is a significant step forward in HIT diagnosis.

STA®-Liatest® FM, the new marker for DIC

To better diagnose DIC and for a reliable vital prognosis, Stago has developed STA®-Liatest® FM, a new quantitative and fully-automated assay for fibrin monomers determination.

A new boosted STA®-ImmunoDef intrinsic factor line

As part of Stago's continuous improvement commitment, STA®-ImmunoDef* intrinsic factor kits were developed as a new generation of Deficient Plasmas with enhanced performances.

Stago Group websites